Your session is about to expire
← Back to Search
Eribulin + Pembrolizumab for Carcinosarcoma (EPOCH Trial)
EPOCH Trial Summary
This trial will study how well a drug and a drug combo work to treat a specific type of cancer and if a protein can predict how the drugs will work.
EPOCH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EPOCH Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have symptoms or diagnosed with severe inflammatory bowel disease.I haven't had any cancer treatment or experimental drugs in the last 4 weeks.I have been treated with eribulin for cancer before.I have not received a live vaccine in the last 30 days.I have another active cancer that could affect the study results.I am willing to have a biopsy for my condition.I am currently being treated for an infection.I had radiotherapy less than 2 weeks before starting the study treatment.I can attend all treatments and follow-up appointments.My organs are functioning well.I have or had lung inflammation that needed steroids.I have been diagnosed with HIV.I am over 18 and have a confirmed diagnosis of tubo-ovarian or uterine carcinosarcoma with at least 5% sarcoma.I have an immune system disorder or have been on steroids or other immune-weakening medicines recently.I have a history of Hepatitis B or active Hepatitis C.I have a tumor sample with more than 30% cancer cells from surgery.I have previously been treated with immunotherapy targeting specific cancer pathways.My cancer returned after 1-2 chemotherapy treatments, confirmed by PET, CT, or MRI.I do not have a second site of disease that can be biopsied.I have an autoimmune disease treated with medication in the last 2 years.I have a tumor that can be measured, not counting the one for biopsy.I have received an organ or tissue transplant from another person.I have a brain tumor or cancer spread to the brain but have been stable for over a month after treatment.I am fully active or restricted in physically strenuous activity but can do light work.My biological samples were taken within the last 28 days.
- Group 1: Arm 1 - Single agent eribulin arm
- Group 2: Arm 2 - Combination eribulin and pembrolizumab arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor open for recruitment?
"Clinicaltrials.gov states that, while initially posted on May 1st 2023 and last updated April 26th 2023, this trial is no longer taking participants. However, 73 other studies are still actively recruiting patients at present."
What potential dangers might individuals face when undergoing the Arm 1 - Single agent eribulin treatment?
"Since only limited evidence is available to demonstrate the safety of Arm 1 - Single agent eribulin, our team at Power has estimated a score of 2. This Phase 2 trial does not have any efficacy data yet."
Are there numerous medical centers conducting the experiment in North America?
"This study is being conducted at 5 sites, including Herston, Clayton and Toronto. Those considering participating in the trial should select a nearby location to reduce travel demands."
Share this study with friends
Copy Link
Messenger